|
시장보고서
상품코드
2128956
유잉 육종 치료 시장 : 치료법별, 약제 클래스별, 투여 경로별, 연령층별, 유통 채널별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)Ewing Sarcoma Therapeutics Market, By Therapy Type, By Drug Class, By Route of Administration, By Age Group, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
유잉 육종 치료 시장 규모는 2025년에 9억 8,020만 달러로 평가되었고, 2026-2033년 CAGR 7.3%로 성장할 전망입니다.
유잉 육종 치료 시장은 유잉 육종이라고도 불리는 희귀암을 치료하는 약물을 의미합니다. 이 의약품 시장에는 일반적으로 소아기, 사춘기 및 청년기에 뼈나 연조직에 발생하는 암을 치료하는 약물이 포함됩니다. 치료법에는 화학요법, 수술, 방사선 요법, 표적 요법, 면역 요법 등 다양한 유형가 있습니다. 전신 요법과 국소 요법을 결합한 다각적인 치료는 생존율을 높이고 재발 가능성을 낮추는 일반적인 치료법입니다. 또한, 분자 종양학 및 희귀암 연구의 발전으로 치료의 가능성도 점차 확대되고 있습니다.
유잉 육종 치료 시장 : 시장 역학
희귀 소아·청소년 암에 대한 연구 관심이 높아지고 있습니다.
희귀암 연구 및 정밀 종양학에 대한 투자 증가는 유잉 육종 치료 시장의 주요 성장 요인으로 작용하고 있습니다. 유잉 육종에서는 특정 염색체 전좌가 관찰되며, 가장 흔한 것은 EWSR1 전좌로, 이를 통해 표적 치료제 개발이 가능해졌습니다. 완전 관해를 유도하는 화학요법이 존재하지 않고, 재감작이 가능하며, 화학요법이 환자에게 미치는 악영향도 입증됨에 따라 표적 치료, 면역 치료, 분자 표적 치료에 대한 연구가 활발히 진행되고 있습니다.
예를 들어, 미국암협회(American Cancer Society)의 보고에 따르면, 미국에서는 매년 약 200명의 소아 및 청소년 환자가 유잉 육종으로 진단받고 있습니다. 이 질환은 비교적 드물지만, 청소년층에서 가장 흔한 골암 중 하나로 꼽힙니다. 희귀 소아암에 대한 노력이 제약 기업, 학술 연구 기관 및 연구 커뮤니티를 뒷받침하며, 새롭고 혁신적인 치료 전략의 추구와 표적 치료제 및 희귀질환 치료제 파이프라인의 확충이 진행되고 있습니다. 정밀 종양학의 전망은 밝으며, 더 효과적이고 개인 맞춤형 유잉 육종 치료법에 대한 수요는 향후 크게 증가할 것으로 예측됩니다.
유잉 육종 치료 시장 : 시장 세분화 분석
세계 유잉 육종 치료 시장은 치료법 유형, 약물 분류, 투여 경로, 연령대, 최종 사용자, 유통 채널 및 지역을 기준으로 세분화되어 있습니다.
화학요법은 여전히 이 질환의 치료에 있어 필수적인 요소이므로, 유잉 육종 치료 시장에서 계속해서 지배적인 위치를 차지하고 있습니다. 실제로 빈크리스틴, 독소르비신, 시클로포스파미드, 이포스파미드, 에토포시드 등 5가지 약물을 조합한 화학요법은 일반적인 치료법이며, 수술이나 방사선 요법과 병용되고 있습니다. 화학요법과 기타 치료법을 결합한 다각적인 접근 방식을 통해 국소성 유잉 육종 환자의 5년 생존율은 70%에 달할 전망입니다.
그러나 이 질환에 대한 분자 수준의 이해가 깊어짐에 따라 표적 치료는 급성장하는 분야가 될 것입니다. 유잉 육종의 생물학적 특성에 특화되어 개발된 저분자 화합물, 키나아제 억제제 및 새로운 표적 치료에 관한 연구 프로그램이 점점 더 많이 시험되고 있습니다.
약제 분류별로 보면, 알킬화제 및 안트라사이클린계 항암제는 1차 치료 프로그램의 주요 구성 요소이므로 여전히 주요 범주로 남아 있습니다. 예를 들어, 미국 종합암네트워크(NCCN) 및 미국 국립암연구소(NCI)가 지지하는 치료 프로토콜에서는 유잉 육종의 주요 치료법으로 여전히 시클로포스파미드, 이포스파미드, 독소루비신이 사용되고 있습니다.
유잉 육종 치료 시장 - 지역별 분석
북미는 선진적인 암 치료 시설의 존재, 활발한 연구 활동, 그리고 희귀질환 연구를 위한 자금이 확보되어 있어 유잉 육종 치료에 있어 중요한 지역 중 하나입니다. 미국 국립암연구소(NCI)에 따르면, 유잉 육종은 전체 소아암의 약 1%를 차지하며, 10세에서 20세 연령대에서 많이 발생합니다. 이 지역에서는 소아 종양학 시설의 존재, 희귀질환용 의약품(희귀의약품)에 대한 매력적인 의약품 개발 정책, 그리고 육종 연구 네트워크 참여를 통해 유잉 육종에 대한 새로운 치료법이 개발 및 도입되었습니다.
또한 유럽에서는 암 연구 분야의 중요한 협력과 희귀질환 치료 프로그램도 전개되고 있습니다. 예를 들어, 유럽임상종양학회(ESMO)는 EURACAN과 마찬가지로 현재도 유럽의 여러 국가에서 육종에 관한 임상 연구 및 치료 지침의 추진에 힘쓰고 있습니다. 또한, 유럽집행위원회는 ‘호라이즌 유럽(Horizon Europe)’의 일환으로 여러 프로그램을 운영하고 있으며, 이러한 프로그램들은 ‘트랜스레이셔널 종양학(Translational Oncology)’ 연구 프로그램을 통해 희귀암 대책 노력의 발전을 지원하고 있습니다. 이 모든 것이 새로운 치료법 개발과 지역 전체의 육종 치료 센터에 대한 접근성 향상으로 이어지고 있습니다.
목차
제1장 유잉 육종 치료 시장 개요
제2장 주요 요약
제3장 유잉 육종 치료 주요 시장 동향
제4장 유잉 육종 치료 산업 분석
제5장 유잉 육종 치료 시장 : 높아지는 지정학적 긴장의 영향
제6장 유잉 육종 치료 시장 구도
제7장 유잉 육종 치료 시장 : 요법 유형별
제8장 유잉 육종 치료 시장 : 약제 클래스별
제9장 유잉 육종 치료 시장 : 투여 경로별
제10장 유잉 육종 치료 시장 : 연령층별
제11장 유잉 육종 치료 시장 : 최종 사용자별
제12장 유잉 육종 치료 시장 : 유통 채널별
제13장 유잉 육종 치료 시장 : 지역별
제14장 주요 벤더 분석 : 유잉 육종 치료 산업
제15장 AnalystView 전방위 전망
AJY 26.09.17Ewing Sarcoma Therapeutics Market size was valued at US$ 980.2 Million in 2025, expanding at a CAGR of 7.3% from 2026 to 2033.
Ewing Sarcoma Therapeutics Market refers to drugs that treat the rare cancer which is otherwise called Ewing sarcoma. The drug market includes the drugs which treat a type of cancer that generally occurs in bones and soft tissues in childhood, adolescence, and early adulthood. There are various types of treatments including chemotherapy, surgery, radiation therapy, target, and immunotherapy. Multimodal therapy which includes the combination of systemic and local therapy is a common type of treatment that increases the probability of survival and decreases the likelihood of recurrence of the disease. There is also increasing possibility of therapy due to advances in molecular oncology and rare cancers.
Ewing Sarcoma Therapeutics Market- Market Dynamics
Increasing Research Focus on Rare Pediatric and Adolescent Cancers
The rising investment in rare cancer research and precision oncology is a key growth factor in the Ewing Sarcoma Therapeutics Market. Ewing sarcoma has certain selected chromosomal translocations, the most common being a translocation of EWSR1, which allows targeted therapeutic development. Targeted treatments, immunotherapy, and molecular targeted therapy have become actively researched since there is no chemotherapy treatment providing full remission and re-sensitisation is possible; furthermore, the negative effects of chemotherapy on patients have also been proven.
As an example, around 200 children and adolescents are diagnosed with Ewing sarcoma annually in the United States, the American Cancer Society reports. Even though the disease is relatively rare, it ranks among the most common bone cancers in adolescents. The commitment to rare pediatric cancers is driving pharmaceutical companies, academic research institutions, and the research community to pursue new and innovative treatment strategies, and improve the pipeline of targeted and orphan drugs. The future of precision oncology is bright, and the need for more effective and personalized Ewing sarcoma therapies is likely to increase greatly.
Ewing Sarcoma Therapeutics Market- Segmentation Analysis:
The Global Ewing Sarcoma Therapeutics Market is segmented on the basis of Therapy Type, Drug Class, Route of Administration, Age Group, End User, Distribution Channel, and Region.
Chemotherapy continues to hold a dominant position in the Ewing Sarcoma Therapeutics Market, since it still remains an essential part of the treatment of the disease. In fact, the combination of chemotherapy with a group of five drugs such as vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide is common practice, being used along with surgery and radiotherapy. As per the multimodal approach that includes both chemotherapy and other kinds of treatment, the 5-year survival rate of localized Ewing sarcoma patients reaches 70%.
But Targeted Therapy will become a high-growth segment due to advanced molecular understanding of the disease. Small-molecule, kinase inhibitor and novel targeted research programs are increasingly being tested that are specifically targeting Ewing's biology.
Alkylating Agents and Anthracyclines are still the primary categories as they are major components of frontline treatment programmes, based on Drug Class. For instance, the National Comprehensive Cancer Network (NCCN) and treatment protocols supported by the National Cancer Institute (NCI) still use cyclophosphamide, ifosfamide and doxorubicin as the main treatment for Ewing sarcoma.
Ewing Sarcoma Therapeutics Market- Geographical Insights
North America holds one of the important regions for the treatment of Ewing Sarcoma because of the presence of advanced cancer care facility, active research works, and funding that is available for rare diseases research. As per the National Cancer Institute of the U.S., Ewing sarcoma constitutes about 1% of all cancers in childhood and is prevalent among 10-20-year-olds. Novel treatment methods for Ewing sarcoma were designed and used in the region owing to the presence of pediatric oncology facilities, attractive drug development policies for orphan drugs, and participation of the region in sarcoma research networks.
There is also significant cancer research collaboration and rare disease treatment programs in Europe. The European Society for Medical Oncology (ESMO), for instance, is still promoting clinical research and treatment guidelines on sarcomas in several European countries, as is EURACAN. The European Commission has also several programmes under Horizon Europe, which help to develop rare cancer initiatives through the Translational Oncology research programme. All of this is leading to new treatments and better access to sarcoma treatment centers across the region.
Ewing Sarcoma Therapeutics Market- Competitive Landscape:
Ewing's Sarcoma Therapeutics Market operates under competitive market dynamics whereby various stakeholders such as oncology drugs, rare disease drugs and biotechnology companies compete with one another on the basis of targeted therapy and immunotherapy. Some of the key players within the market include Bristol Myers Squibb, Pfizer Inc., Merck & Co., Johnson & Johnson, Roche Holding AG, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company, Amgen Inc. and Bayer AG among others. Competitors in the market have started competing through molecules, combinations, and orphan drugs.
Recent Developments:
In March of 2026, C-Further announced its first therapeutic programmes in early stages for paediatric oncology. The consortium has teaming agreements with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute, and Mass General Brigham to further develop CF-012 to potentially treat Ewing sarcoma. It has also collaborated with MiNK Therapeutics to develop CF-033 for a number of paediatric cancers.
In December 2025, Inhibrx Biosciences has shared progress updates for INBRX-106 and ozekibart. The company shared updates on clinical trials with Keytruda in refractory Ewing sarcoma and in late-line colorectal cancer, using ozekibart in combination with FOLFIRI, as well as updates on clinical trials using ozekibart in combination with irinotecan and temozolomide for refractory Ewing sarcoma.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL EWING SARCOMA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Gradalis, Inc.
- Pfizer Inc.
- Bristol Myers Squibb
- BioAtla, Inc.
- Cellectar Biosciences
- Inhibrx Biosciences, Inc.
- Eisai Co., Ltd.
- Amgen Inc.
- Y-mAbs Therapeutics, Inc.
- Oncoheroes Biosciences
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Johnson & Johnson
- AstraZeneca plc
- Sanofi
- Eli Lilly and Company
- Daiichi Sankyo Company, Limited
- Jazz Pharmaceuticals plc
- PharmaMar, S.A.
- Others
GLOBAL EWING SARCOMA THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2020 - 2033
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Surgical Intervention
- Supportive Care
- Others
GLOBAL EWING SARCOMA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Alkylating Agents
- Anthracyclines
- Topoisomerase Inhibitors
- Antimetabolites
- Targeted Small Molecules
- Monoclonal Antibodies
GLOBAL EWING SARCOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Intravenous
- Oral
- Injectable / Parenteral
GLOBAL EWING SARCOMA THERAPEUTICS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2020 - 2033
- Pediatric
- Adolescent & Young Adult (AYA)
- Adult
GLOBAL EWING SARCOMA THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Specialty Cancer Centers
- Ambulatory Surgical Centers
- Academic & Research Institutes
GLOBAL EWING SARCOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL EWING SARCOMA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Table of Contents
1. Ewing Sarcoma Therapeutics Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.2. Competitive Insights
3. Ewing Sarcoma Therapeutics Key Market Trends
- 3.1. Ewing Sarcoma Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Ewing Sarcoma Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Ewing Sarcoma Therapeutics Market Opportunities
- 3.4. Ewing Sarcoma Therapeutics Market Future Trends
4. Ewing Sarcoma Therapeutics Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Ewing Sarcoma Therapeutics Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Ewing Sarcoma Therapeutics Market Landscape
- 6.1. Ewing Sarcoma Therapeutics Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Ewing Sarcoma Therapeutics Market - By Therapy Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapy Type, 2025 & 2033 (%)
- 7.1.2. Chemotherapy
- 7.1.3. Targeted Therapy
- 7.1.4. Immunotherapy
- 7.1.5. Radiation Therapy
- 7.1.6. Surgical Intervention
- 7.1.7. Supportive Care
- 7.1.8. Others
8. Ewing Sarcoma Therapeutics Market - By Drug Class
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
- 8.1.2. Alkylating Agents
- 8.1.3. Anthracyclines
- 8.1.4. Topoisomerase Inhibitors
- 8.1.5. Antimetabolites
- 8.1.6. Targeted Small Molecules
- 8.1.7. Monoclonal Antibodies
9. Ewing Sarcoma Therapeutics Market - By Route of Administration
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 9.1.2. Intravenous
- 9.1.3. Oral
- 9.1.4. Injectable / Parenteral
10. Ewing Sarcoma Therapeutics Market - By Age Group
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
- 10.1.2. Pediatric
- 10.1.3. Adolescent & Young Adult (AYA)
- 10.1.4. Adult
11. Ewing Sarcoma Therapeutics Market - By End User
- 11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
- 11.1.2. Hospitals
- 11.1.3. Specialty Cancer Centers
- 11.1.4. Ambulatory Surgical Centers
- 11.1.5. Academic & Research Institutes
12. Ewing Sarcoma Therapeutics Market - By Distribution Channel
- 12.1. Overview
- 12.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
- 12.1.2. Hospital Pharmacies
- 12.1.3. Retail Pharmacies
- 12.1.4. Online Pharmacies
13. Ewing Sarcoma Therapeutics Market- By Geography
- 13.1. Introduction
- 13.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 13.2. North America
- 13.2.1. Overview
- 13.2.2. Ewing Sarcoma Therapeutics Key Manufacturers in North America
- 13.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 13.2.4. North America Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.2.5. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.2.6. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.2.7. North America Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.2.8. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.2.9. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.2.10. U.S.
- 13.2.10.1. Overview
- 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.2.10.3. U.S. Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.2.10.4. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.2.10.5. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.2.10.6. U.S. Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.2.10.7. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.2.10.8. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.2.11. Canada
- 13.2.11.1. Overview
- 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.2.11.3. Canada Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.2.11.4. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.2.11.5. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.2.11.6. Canada Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.2.11.7. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.2.11.8. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3. Europe
- 13.3.1. Overview
- 13.3.2. Ewing Sarcoma Therapeutics Key Manufacturers in Europe
- 13.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 13.3.4. Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.5. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.6. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.7. Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.8. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.9. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.10. Germany
- 13.3.10.1. Overview
- 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.10.3. Germany Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.10.4. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.10.5. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.10.6. Germany Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.10.7. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.10.8. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.11. UK
- 13.3.11.1. Overview
- 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.11.3. UK Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.11.4. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.11.5. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.11.6. UK Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.11.7. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.11.8. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.12. France
- 13.3.12.1. Overview
- 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.12.3. France Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.12.4. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.12.5. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.12.6. France Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.12.7. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.12.8. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.13. Italy
- 13.3.13.1. Overview
- 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.13.3. Italy Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.13.4. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.13.5. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.13.6. Italy Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.13.7. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.13.8. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.14. Spain
- 13.3.14.1. Overview
- 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.14.3. Spain Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.14.4. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.14.5. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.14.6. Spain Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.14.7. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.14.8. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.15. The Netherlands
- 13.3.15.1. Overview
- 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.15.3. The Netherlands Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.15.4. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.15.5. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.15.6. The Netherlands Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.15.7. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.15.8. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.16. Sweden
- 13.3.16.1. Overview
- 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.16.3. Sweden Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.16.4. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.16.5. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.16.6. Sweden Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.16.7. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.16.8. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.17. Russia
- 13.3.17.1. Overview
- 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.17.3. Russia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.17.4. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.17.5. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.17.6. Russia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.17.7. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.17.8. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.18. Poland
- 13.3.18.1. Overview
- 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.18.3. Poland Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.18.4. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.18.5. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.18.6. Poland Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.18.7. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.18.8. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.19. Denmark
- 13.3.19.1. Overview
- 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.19.3. Denmark Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.19.4. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.19.5. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.19.6. Denmark Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.19.7. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.19.8. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.3.20. Rest of Europe
- 13.3.20.1. Overview
- 13.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.3.20.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.3.20.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.3.20.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.3.20.6. Rest of the Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.3.20.7. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.3.20.8. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4. Asia Pacific (APAC)
- 13.4.1. Overview
- 13.4.2. Ewing Sarcoma Therapeutics Key Manufacturers in Asia Pacific
- 13.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 13.4.4. APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.5. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.6. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.7. APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.8. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.9. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.10. China
- 13.4.10.1. Overview
- 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.10.3. China Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.10.4. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.10.5. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.10.6. China Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.10.7. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.10.8. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.11. India
- 13.4.11.1. Overview
- 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.11.3. India Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.11.4. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.11.5. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.11.6. India Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.11.7. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.11.8. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.12. Japan
- 13.4.12.1. Overview
- 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.12.3. Japan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.12.4. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.12.5. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.12.6. Japan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.12.7. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.12.8. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.13. South Korea
- 13.4.13.1. Overview
- 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.13.3. South Korea Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.13.4. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.13.5. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.13.6. South Korea Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.13.7. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.13.8. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.14. Australia
- 13.4.14.1. Overview
- 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.14.3. Australia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.14.4. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.14.5. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.14.6. Australia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.14.7. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.14.8. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.15. Indonesia
- 13.4.15.1. Overview
- 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.15.3. Indonesia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.15.4. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.15.6. Indonesia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.15.7. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.15.8. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.16. Thailand
- 13.4.16.1. Overview
- 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.16.3. Thailand Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.16.4. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.16.5. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.16.6. Thailand Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.16.7. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.16.8. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.17. Philippines
- 13.4.17.1. Overview
- 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.17.3. Philippines Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.17.4. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.17.5. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.17.6. Philippines Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.17.7. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.17.8. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.18. Taiwan
- 13.4.18.1. Overview
- 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.18.3. Taiwan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.18.4. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.18.5. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.18.6. Taiwan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.18.7. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.18.8. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.19. Vietnam
- 13.4.19.1. Overview
- 13.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.19.3. Vietnam Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.19.4. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.19.5. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.19.6. Vietnam Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.19.7. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.4.19.8. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.4.20. Rest of APAC
- 13.4.20.1. Overview
- 13.4.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.4.20.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.4.20.4. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.4.20.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.4.20.6. Rest of APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.4.20.7. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.5. Latin America (LATAM)
- 13.5.1. Overview
- 13.5.2. Ewing Sarcoma Therapeutics Key Manufacturers in Latin America
- 13.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 13.5.4. LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.5.5. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.5.6. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.5.7. LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.5.8. LATAM Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.5.9. LATAM Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.5.10. Brazil
- 13.5.10.1. Overview
- 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.5.10.3. Brazil Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.5.10.4. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.5.10.5. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.5.10.6. Brazil Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.5.10.7. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.5.10.8. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.5.11. Mexico
- 13.5.11.1. Overview
- 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.5.11.3. Mexico Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.5.11.4. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.5.11.5. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.5.11.6. Mexico Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.5.11.7. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.5.11.8. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.5.12. Argentina
- 13.5.12.1. Overview
- 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.5.12.3. Argentina Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.5.12.4. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.5.12.5. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.5.12.6. Argentina Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.5.12.7. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.5.12.8. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.5.13. Colombia
- 13.5.13.1. Overview
- 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.5.13.3. Colombia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.5.13.4. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.5.13.5. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.5.13.6. Colombia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.5.13.7. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.5.13.8. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.5.14. Rest of LATAM
- 13.5.14.1. Overview
- 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.5.14.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.5.14.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.5.14.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.5.14.6. Rest of LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.5.14.7. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.5.14.8. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6. Middle East and Africa
- 13.6.1. Overview
- 13.6.2. Ewing Sarcoma Therapeutics Key Manufacturers in Middle East and Africa
- 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 13.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.7. Middle East and Africa Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.8. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.9. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.10. Saudi Arabia
- 13.6.10.1. Overview
- 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.10.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.10.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.10.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.10.6. Saudi Arabia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.10.7. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.10.8. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.11. United Arab Emirates
- 13.6.11.1. Overview
- 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.11.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.11.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.11.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.11.6. United Arab Emirates Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.11.7. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.11.8. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.12. Israel
- 13.6.12.1. Overview
- 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.12.3. Israel Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.12.4. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.12.5. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.12.6. Israel Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.12.7. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.12.8. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.13. Turkey
- 13.6.13.1. Overview
- 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.13.3. Turkey Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.13.4. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.13.5. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.13.6. Turkey Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.13.7. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.13.8. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.14. Algeria
- 13.6.14.1. Overview
- 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.14.3. Algeria Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.14.4. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.14.5. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.14.6. Algeria Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.14.7. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.14.8. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.15. Egypt
- 13.6.15.1. Overview
- 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.15.3. Egypt Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.15.4. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.15.5. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.15.6. Egypt Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.15.7. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.15.8. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.16. Iran
- 13.6.16.1. Overview
- 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.16.3. Iran Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.16.4. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.16.5. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.16.6. Iran Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.16.7. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.16.8. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.17. Qatar
- 13.6.17.1. Overview
- 13.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.17.3. Qatar Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.17.4. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.17.5. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.17.6. Qatar Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.17.7. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.17.8. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 13.6.18. Rest of MEA
- 13.6.18.1. Overview
- 13.6.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
- 13.6.18.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 13.6.18.4. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 13.6.18.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 13.6.18.6. Rest of MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
- 13.6.18.7. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 13.6.18.8. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
14. Key Vendor Analysis- Ewing Sarcoma Therapeutics Industry
- 14.1. Competitive Benchmarking
- 14.1.1. Competitive Dashboard
- 14.1.2. Competitive Positioning
- 14.2. Company Profiles
- 14.2.1. Gradalis, Inc.
- 14.2.2. Pfizer Inc.
- 14.2.3. Bristol Myers Squibb
- 14.2.4. BioAtla, Inc.
- 14.2.5. Cellectar Biosciences
- 14.2.6. Inhibrx Biosciences, Inc.
- 14.2.7. Eisai Co., Ltd.
- 14.2.8. Amgen Inc.
- 14.2.9. Y-mAbs Therapeutics, Inc.
- 14.2.10. Oncoheroes Biosciences
- 14.2.11. Novartis AG
- 14.2.12. F. Hoffmann-La Roche Ltd.
- 14.2.13. Merck & Co., Inc.
- 14.2.14. Johnson & Johnson
- 14.2.15. AstraZeneca plc
- 14.2.16. Sanofi
- 14.2.17. Eli Lilly and Company
- 14.2.18. Daiichi Sankyo Company, Limited
- 14.2.19. Jazz Pharmaceuticals plc
- 14.2.20. PharmaMar, S.A.
- 14.2.21. Others
15. 360 Degree Analyst View
16. Appendix
- 16.1. Research Methodology
- 16.2. References
- 16.3. Abbreviations
- 16.4. Disclaimer
- 16.5. Contact Us
